Pennsylvania Law Mandates No-Cost Coverage for Colorectal Cancer Blood Tests
A new Pennsylvania law will require state-regulated insurers and Medicaid to cover blood-based colorectal cancer screening tests with no cost-sharing, Dec 21, 2026.
A new Pennsylvania law will require state-regulated insurers and Medicaid to cover blood-based colorectal cancer screening tests with no cost-sharing, Dec 21, 2026.
Labcorp will acquire select BioReference Health assets from OPKO Health for $722 million, including clinical, urology, and women’s health labs, 80+ patient service centers, and the FDA-approved 4Kscore prostate cancer test.
CMS has released preliminary 2027 CLFS rates, with data showing weighted median payment cuts for over 1,100 test codes; annual reductions are capped at 15% from 2027 to 2029 under current policy.
The College of American Pathologists has updated 14 Cancer Protocols, mandating the Breast Phyllodes Tumor protocol for accreditation and revising breast biomarker and GIST molecular testing criteria, according to CAP.
A global survey of 231 labs in 41 countries, published by IOF and IFCC, reveals significant inconsistencies in bone biomarker testing methods, reference intervals, and quality assessments, highlighting a need for greater harmonization.
Lot-to-lot reagent inconsistencies can have significant effects on patient test results.
CND Life Sciences has opened a dedicated Innovation Laboratory in Scottsdale, Ariz., to expand assay development and biomarker research for neurodegenerative diseases, operating separately from its CLIA-certified clinical lab.
Urinalysis comparison guide featuring testing capabilities, technology, throughput, connectivity, sample capacity, and key specifications from leading systems.